INTRODUCTION
Preterm birth continues to be a problem for obstetricians. Preterm birth complicates 8 -10% of birth. 1 Although the causes of preterm labour are not well understood, the burden of preterm birth is clear. The majority of neonatal deaths and over one third of infant deaths are linked to preterm birth. Methods to detect preterm labour at early stage include ultrasound examination of cervix and detection of biochemical markers of preterm labour in blood, saliva and cervicovaginal secretion. Given the methods to predict and prevent preterm birth are imperfect, attention focuses on the treatment of women admitted with preterm labour. The most beneficial intervention in these cases is antenatal corticosteroid. Antenatal corticosteroids have been clearly demonstrated to reduce neonatal mortality and multiple morbidities.
Thus the primary goal of tocolytic therapy has been to maintain the pregnancy for at least 48 hours to enable administration of antenatal corticosteroid. No evidence exists that tocolytic therapy directly benefits neonatal outcomes. However, short term tocolytic therapy has been demonstrated to be superior to placebo in prolonging pregnancy for at least 48 hours. David M Haas et al. described the role of short term tocolytics for preterm deliveries.
2 Short-term use of tocolytic drugs is common in order to prolong pregnancy long enough for effective antenatal corticosteroids and other therapies to be administered. Multiple classes and drugs are utilized, mainly because many demonstrate similar efficacy.preventing neonatal complication. However, these results are from meta-analyses and not direct trials using all drug classes and thus must be interpreted carefully. In addition, because of concerns about premature closure of the fetal ductus, prostaglandin inhibitors are seldom used in practice after 32 week. Short-term tocolytic therapy should be individualized to the patient and her particular circumstances and the potential for side effect. Pharmacogenetic principles have been explored in relation to tocolytic drugs like nifedipine. These may give us a glimpse into the future of obstetric therapeutics and more individualization of pharmacotherapy during pregnancy. No matter which tocolytic agent the clinician chooses, the evidence supports the use of short-term tocolytic drugs to prolong pregnancy for at least 48 hours to allow for administration of antenatal steroids. This may also allow for transport of the mother to a tertiary care facility and for administration of magnesium sulfate to reduce the risk of cerebral palsy. While many trials have used tocolytics for longer periods of time, those that analyzed prolonged courses of tocolytics have generally failed to demonstrate benefit. So while the choice of firstline agent may not be clear, it is evident that short-term tocolysis is an effective and helpful therapy for women in preterm labor.
METHODS
This observational study was done in patients of preterm labour in Upper India Sugar Exchange Maternity Hospital, Kanpur. Present study comprised of a total of 200 cases of preterm labour. Out of these, 60 patients were treated with ritodrine, 50 with isoxsuprine, 30 with nifedepine, 30 with glyceryltrinitrate and 30 with magnesium sulphate.
Following were with exclusion criteria of present study:
 Multiple gestation  A plan to move out of the area before delivery  History of associated infection and inflammation  Hormone use  Metabolic syndrome  Medication use (particularly statins, fibrates, neacin)  Cardiovascular disease
RESULTS
In our study calcium channel blocker were associated with statistically and clinically significantly better neonatal outcomes and fewer maternal side effects than any other tocolytic so calcium channel blocker would be preferred first line tocolytic with regard to several important outcomes. Table 2 ). In our study the gestational age on admission nifedepine group was 30.06 ± 2.85 weeks as compared to 35.00 ± 2.94 was on delivery. This was statistically significant. These studies are in accordance with as of King JF et al., who showed that delivery was delayed with nifedepine. 4 In nifedepine group the duration of prolongation of pregnancy was 49.38 ± 25.49 and 64 ± 4.17 days with cervical dilatation > 2cm. This difference was also statistically significant. In glyceryltrinitrate group the duration of prolongation of pregnancy was 53.29 ± 26.25 days with cervical dilatation <2cm and 4.3 ± 4.18 days with cervical dilatation >2cm. This shows that the drug was found to be more effective with lesser cervical dilatation. These were comparable to the results of Lees et al., who reported that patients with cervical >2cm were at higher risk of imminent delivery. 5 Nifedepine showed an increases in maternal heart rate in 6.6% patients and hypotension decrease in (diastolic blood prescribe) in 13.3% patient. Our findings are similar to a study by King et al. 4 They suggested that calcium channel blocker are associated with statistically and clinically significantly better neonatal outcome and fewer maternal side effect than any other tocolytic so calcium channel blocker would be preferred first line tocolytic with regard to several important outcome. In our study maximum number of babies had Apgar score between 8 and 10 at 5 minute. Mean Apgar score at 5 minute was 8.1 ± 2.20, 8.2 ± 2.00, 7.9 ± 2.39, 7.9 ± 2.39, 7.6 ± 2.34 in ritodrine, isoxsuprine, nifedepine, glycerlynitrate and magnesium sulphate group respectively (Table 6 ). Mean birth weight of babies born to mother were 2341 ± 552.1, 2215 ± 560.4, 2166 ± 541, 2116 ± 576.4 and 2108 ± 578.7 gm respectively in ritodrine, isoxsuprine, nifedepine, glycerlynitrate and magnesium sulphate group respectively (Table 6 ).
